Evidence map›Paper›PMID 37438018›Full record

ArticleInternational review of cell and molecular biology2023

Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy.

Chang Su, Jonathon E Himes, David G Kirsch

Abstract read
In one paragraph

Article in International review of cell and molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chang SuMolecular Cancer Biology Program and Medical Scientist Training Program, Duke University School of Medicine, Durham, NC, United States.
Jonathon E HimesMolecular Cancer Biology Program and Medical Scientist Training Program, Duke University School of Medicine, Durham, NC, United States.
David G KirschDepartment of Radiation Oncology, Duke University School of Medicine, Durham, NC, United States; Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, United States. Electronic address: david.kirsch@duke.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Dissecting the Role of Radiation in Regulation of MHC-I and Neoantigen PresentationF30CA268910 · NCI · DUKE UNIVERSITY · PI SU, CHANG · 2022 to 2025
$156k
NCI NIH HHS F30 CA268910NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

Activating and recruiting the immune system is critical for successful cancer treatment. Since the discovery of immune checkpoint inhibitors, immunotherapy has become the standard of care for many types of cancers. However, many patients fail to respond to immunotherapy. Further research is needed to understand the mechanisms of resistance and adjuvant therapies that can help sensitize patients to immunotherapies. Here, we will discuss how radiotherapy can change the tumor microenvironment and work synergistically with immunotherapy. We will examine different pre-clinical models focusing on their limitations and their unique advantages in studying the efficacy of treatments and the tumor microenvironment. We will also describe emerging findings from clinical trials testing the combination of immunotherapy and radiotherapy.

Indexed as

ImmunotherapyTumor MicroenvironmentHumansClinical trialsGEMMImmune checkpoint blockadeImmunotherapyPreclinical modelsRadiation therapyRadiotherapyTumor microenvironment

Identifiers

PMID37438018
PMCPMC10710768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.